Evotec SE (LON:0IRF)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 467.55M -42.8% |
| Revenue (ttm) | 614.42M -5.0% |
| Net Income | -154.57M |
| EPS | -0.85 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,268 |
| Open | 3.188 |
| Previous Close | 3.134 |
| Day's Range | 3.118 - 3.200 |
| 52-Week Range | 2.414 - 6.680 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Financial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial numbers in EUR Financial StatementsNews
EQS-CMS: Evotec SE: Release of a capital market information
EQS Post-admission Duties announcement: Evotec SE / Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052...
Evotec price target raised to $5 from $4 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Evotec (EVO) to $5 from $4 and keeps a Buy rating on the shares. The firm cites improved expectations for revenue growth…
Evotec SE (EVO) Q3 2026 Earnings Call Transcript
Q3 loss narrowed on cost cuts, and a new Vertex manufacturing win.
What Evotec (EVO) Said on Its Q3 Earnings Call
Evotec NASDAQ: EVO reported a narrower adjusted EBITDA loss for the third quarter of 2026 and reaffirmed its full-year guidance, saying it expects revenue and earnings to finish toward the upper ends ...
Evotec Reports Q3 EBITDA Improvement; Reaffirms FY26 Guidance And Outlines 2030 Growth Targets
(RTTNews) - Evotec SE (EVO), a drug discovery and development company, reported third-quarter and nine-month 2026 financial results, highlighting improved quarterly profitability, stronger commercial ...
Evotec SE Earnings Call Transcript: Q3 2026
Q3 revenue improved sequentially and adjusted EBITDA neared break-even, while D&PD commercial indicators strengthened. FY 2026 guidance was reaffirmed toward the upper end; the 2030 plan targets ~€1bn revenue and >20% adjusted EBITDA margin.
Evotec SE Quarterly report: Q3 2026
Evotec SE has published its Q3 2026 quarterly earnings report on November 5, 2026.
Evotec SE Slides: Q3 2026
Evotec SE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m,...
Evotec's Q3 2026 Results: Growth Momentum Builds Toward 2030
Evotec’s Q3 adjusted EBITDA improved sharply on steady revenue, as the company reaffirmed its 2026 outlook and advanced its transformation and strategic partnerships.
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine mon...
Evotec to Unveil 9-Month 2026 Results on November 5
A closer look at Evotec’s progress: The company will present its nine-month 2026 results and a business update during an English-language webcast on November 5.
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 28.10...
Evotec appoints Joanna Holbrook as chief scientific officer
Evotec (EVO) announced the appointment of Joanna Holbrook as chief scientific officer and member of the management board, effective November 1. Holbrook brings to Evotec more than 25 years of…
Evotec Appoints Former Novo Nordisk Executive Joanna Holbrook As Chief Scientific Officer; Stock Up
(RTTNews) - Evotec SE (EVO, EVTG.DE, EVTCY.PK), a life science company, announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and member of the management board, effective Novem...
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of glob...
Evotec Sees 9-Month Results Above Market; Reiterates FY26 Outlook
(RTTNews) - Evotec SE (EVTG.DE, EVTCY.PK, EVO), a German healthcare company, announced preliminary results for the first nine months of 2026 that came in above market expectations, while reaffirming i...
Evotec's Preliminary 9-Month Results Beat Expectations; 2026 Guidance Holds
Evotec’s preliminary nine-month results beat market expectations, with revenue near €465 million and adjusted EBITDA of –€42.8 million, while its 2026 outlook remains unchanged.
EQS-Adhoc: Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
EQS-Ad-hoc: Evotec SE / Key word(s): Forecast / Other Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance 13-Oct-2026 / 22:37 C...
Evotec Announces Chief Scientific Officer Transition
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today an...
Evotec SE Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Scientific expertise and broad offerings differentiate the business, but clearer market messaging is needed. The Horizon program targets €75 million in savings and operational simplification, while new licensing and strategic deals are expected to drive margin growth. Key milestones include delivering on Horizon and clarifying segment dynamics.
Evotec initiates clinical trial evaluating JST-018
Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO sub...
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermea...
Evotec, Plectonic Biotech announce immunotherapy research collaboration
Evotec (EVO) and Plectonic Biotech announced a research collaboration to explore an immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the suc...
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco design...